AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS

Trial Profile

AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 18 Mar 2017 Results of pharmacokinetic data from two long-term phase III studies presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 06 Mar 2017 Results (n=1491) assessing efficacy and safety, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 27 Feb 2017 Data from this trial will be presented at the Annual Meeting of the American Academy of Asthma, Allergy, and Immunology (AAAAI) 2017, according to a Sanofi and Regeneron joint media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top